The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Browse by »
Ergots, ergot alkaloids, ergolines
Valvular heart disease and/or dysfunction
Last update :
Drug and radiation history
Drug singularity - Correct identification of the drug
Consistent timing of exposure v. onset of symptoms
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
Careful exlusion of another cause
Remission of symptoms with removal of drug
Recurrence with rechallenge (rarely advisable)
More detailed checklist
See also under
Drug-induced valvular heart disease: an update.
Ergotamine-associated valvulopathy with recurrent chylous pleural effusion.
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Drug-induced fibrotic valvular heart disease.
Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.
Mitral valve disease associated with long-term ergotamine use.
Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.